Information Provided By: 
Fly News Breaks for November 22, 2019
BHVN
Nov 22, 2019 | 07:23 EDT
Wedbush analyst Laura Chico initiated coverage of Biohaven Pharmaceutical with an Outperform rating and $75 price target. In a research note to investors, Chico says that she sees an attractive setup for shares with the potential arrival of oral, small molecule-targeted CGRP therapies that represents another step forward and with Biohaven's rimegepant under FDA review now. She models approval of rimegepant in FY20, with WW total revenue reaching $1.8B in FY27.
News For BHVN From the Last 2 Days
BHVN
Apr 25, 2024 | 10:38 EDT
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Biohaven Pharmaceutical... To see the rest of the story go to thefly.com. See Story Here
BHVN
Apr 23, 2024 | 09:00 EDT
UBS raised the firm's price target on Biohaven to $60 from $59 and keeps a Buy rating on the shares after hosting meetings with management. The stock's 28% selloff since April 15 represents an "attractive opportunity," the analyst tells investors in a research note. The firm sees an attractive risk/reward into the Phase 1 degrader data on May 29. A key opinion leader viewed Biohaven's degrader platform as an elegant approach to various disease modalities, says UBS. The firm says the stock's bear case is overdone.
